Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

Application of Deauville or Hopkins visual 5-point scale in response assessment of esophageal cancer receiving neoadjuvant chemotherapy and surgery

Mitsuaki Tatsumi, Kayako Isohashi, Hiroki Kato, Tadashi Watabe and Jun Hatazawa
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 493;
Mitsuaki Tatsumi
4Osaka University Graduate School of Medicine Suita/ Osaka Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kayako Isohashi
2Suita City Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroki Kato
1Osaka Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadashi Watabe
5Nuclear Medicine and Tracer Kinetics Osaka University Graduate School of Medicine Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Hatazawa
3Osaka University Graduate School of Medicine Suita, Osaka Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

493

Objectives: Deauville visual 5-point scale (DS) on FDG PET is adopted as a new response assessment method of lymphoma in the Lugano classification published in 2014. Similar visual scale was reported to be useful in head and neck cancer as Hopkins criteria (HC). The purpose of this study was to evaluate if DS or HC was applicable in response assessment of esophageal cancer (EC) receiving neoadjuvant chemotherapy (NAC) and surgery.

Methods: FDG PET-CT examinations were performed before and after 2 cycles of NAC in 41 EC patients before surgery. SUVmax of EC lesion was obtained in each exam and reduction of SUVmax after NAC was calculated. Patients with reduction of SUVmax 蠅30% were defined as responders. PET images after NAC were evaluated regarding residual disease using DS and HC. In the evaluation with DS, two patterns were tested as a definition of non-residual disease: scores 1 and 2 (uptake &#8804; mediastinum) [D1] or scores 1, 2, and 3 (uptake > mediastinum but &#8804; liver) [D2]. HC scores are as follows: 1- FDG uptake < blood pool(bp); 2- focal uptake > bp but < liver; 3- diffuse uptake > bp or liver; 4- focal uptake > liver; 5- focal and intense uptake. HC scores 1, 2, and 3 were considered to represent non-residual disease although scores 3 and 4 both showed uptake > liver (diffuse vs. focal). Results provided with these scores were compared to the reduction of SUVmax and pathologic results after NAC as well as recurrence within 1 year after subsequent surgery. Statistical analysis was performed with a McNemar test.

Results: D1, D2, and HC provided results of residual disease respectively in 31, 25, and 23 pts after NAC. 33 (80%) of 41 pts were considered as responders with reduction of SUVmax after NAC (蠅70% reduction in 16 of them). Although exhibiting mixed results even in responders with 蠅70% SUVmax reduction, D1, D2, and HC provided results of residual disease in all 8 non-responders. Good pathologic response (viable cancer cells: < 1/3 of specimens) was achieved in 5 (12%) pts and recurrence was observed in 19 (46%) of the 41 pts. D1 exhibited significantly higher accuracy (73%, p <0.05) than D2 (59%) or HC (59%) in evaluating pathologic response, if non-good pathologic response was regarded as residual disease. HS exhibited significantly higher accuracy (66%, p <0.01) than D1 (46%) in evaluating recurrence (D2: 61%).

Conclusion: This study demonstrated both DS and HC were applicable in response assessment of EC after NAC. DS had the promise in evaluating pathologic response, when uptake > mediastinum was treated as residual disease. HC was useful in predicting recurrence in this study population. Research Support:

View this table:
  • View inline
  • View popup

PET visual scale analysis vs. pathologic response after NAC

View this table:
  • View inline
  • View popup

PET visual scale analysis vs. recurrence after surgery within 1 yr

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 58, Issue supplement 1
May 1, 2017
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Application of Deauville or Hopkins visual 5-point scale in response assessment of esophageal cancer receiving neoadjuvant chemotherapy and surgery
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Application of Deauville or Hopkins visual 5-point scale in response assessment of esophageal cancer receiving neoadjuvant chemotherapy and surgery
Mitsuaki Tatsumi, Kayako Isohashi, Hiroki Kato, Tadashi Watabe, Jun Hatazawa
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 493;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Application of Deauville or Hopkins visual 5-point scale in response assessment of esophageal cancer receiving neoadjuvant chemotherapy and surgery
Mitsuaki Tatsumi, Kayako Isohashi, Hiroki Kato, Tadashi Watabe, Jun Hatazawa
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 493;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of SUVmax
Show more Oncology, Clinical Diagnosis Track

GI-Non-colorectal

  • Prognostic value and multivariate analysis of body composition measures on 18F-FDG PET/CT imaging in patients with esophageal adenocarcinoma
  • Prognostic Significance of 18F-FDG PET/CT in Patients with Distal Bile Duct Cancer undergoing Curative Surgery
  • Dynamic 18F-FDG PET response to preoperative neoadjuvant chemotherapy in potentially resectable pancreatic ductal adenocarcinoma may predict overall survival
Show more GI-Non-colorectal

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire